<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>A system pharmacology multi-omics approach toward uncontrolled pediatric asthma</dc:title><dc:creator>Abdel-Aziz,	Mahmoud I.	(Avtor)
	</dc:creator><dc:creator>Gorenjak,	Mario	(Avtor)
	</dc:creator><dc:creator>Potočnik,	Uroš	(Avtor)
	</dc:creator><dc:subject>pediatric asthma</dc:subject><dc:subject>uncontrolled asthma</dc:subject><dc:subject>omics</dc:subject><dc:subject>systems medicine</dc:subject><dc:description>There is a clinical need to identify children with poor asthma control as early as possible, to optimize treatment and/or to find therapeutic alternatives. Here, we present the “Systems Pharmacology Approach to Uncontrolled Pediatric Asthma” (SysPharmPediA) study, which aims to establish a pediatric cohort of moderate-to-severe uncontrolled and controlled patients with asthma, to investigate pathophysiological mechanisms underlying uncontrolled moderate-to-severe asthma in children on maintenance treatment, using a multi-omics systems medicine approach. In this multicenter observational case–control study, moderate-to-severe asthmatic children (age; 6–17 years) were included from four European countries (Netherlands, Germany, Spain, and Slovenia). Subjects were classified based on asthma control and number of exacerbations. Demographics, current and past patient/family history, and clinical characteristics were collected. In addition, systems-wide omics layers, including epi(genomics), transcriptomics, microbiome, proteomics, and metabolomics were evaluated from multiple samples. In all, 145 children were included in this cohort, 91 with uncontrolled (median age = 12 years, 43% females) and 54 with controlled asthma (median age = 11.7 years, 37% females). The two groups did not show statistically significant differences in age, sex, and body mass index z-score distribution. Comprehensive information and diverse noninvasive biosampling procedures for various omics analyses will provide the opportunity to delineate underlying pathophysiological mechanisms of moderate-to-severe uncontrolled pediatric asthma. This eventually might reveal novel biomarkers, which could potentially be used for noninvasive personalized diagnostics and/or treatment.</dc:description><dc:date>2021</dc:date><dc:date>2023-08-02 09:05:56</dc:date><dc:type>Znanstveno delo</dc:type><dc:identifier>84865</dc:identifier><dc:identifier>UDK: 616.248</dc:identifier><dc:identifier>COBISS_ID: 65569795</dc:identifier><dc:identifier>DOI: 10.3390/jpm11060484</dc:identifier><dc:identifier>ISSN pri članku: 2075-4426</dc:identifier><dc:language>sl</dc:language></metadata>
